Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nicolas Solban

Showing results (21-30 of 25) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 25 results.
The New England Journal of Medicine|June 30, 2016
Cortical-Bone Fragility--Insights from sFRP4 Deficiency in Pyle's DiseasePelin O Simsek Kiper, Hiroaki Saito, Francesca Gori, et al.
ACS Medicinal Chemistry Letters|November 22, 2019
Discovery of Amino-cyclobutarene-derived Indoleamine-2,3-dioxygenase 1 (IDO1) Inhibitors for Cancer ImmunotherapyHongjun Zhang, Kun Liu, Qinglin Pu, et al.
Journal of Medicinal Chemistry|June 26, 2024
Discovery of MK-1084: An Orally Bioavailable and Low-Dose KRAS<sup>G12C</sup> InhibitorXiaoshen Ma, David L Sloman, Ruchia Duggal, et al.
Journal of Medicinal Chemistry|April 9, 2026
From KRAS<sup><i>G12D</i></sup> to Pan-KRAS Inhibitors─A Journey Enabled by Synthetic Innovation and Structure-Based Drug DesignXiaoshen Ma, David L Sloman, Timothy J Henderson, et al.
Journal of Medicinal Chemistry|March 3, 2022
Oxetane Promise Delivered: Discovery of Long-Acting IDO1 Inhibitors Suitable for Q3W Oral or Parenteral DosingDerun Li, David L Sloman, Abdelghani Achab, et al.
Pageof 3

Showing results (21-30 of 25) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 25 results.
The New England Journal of Medicine|June 30, 2016
Cortical-Bone Fragility--Insights from sFRP4 Deficiency in Pyle's DiseasePelin O Simsek Kiper, Hiroaki Saito, Francesca Gori, et al.
ACS Medicinal Chemistry Letters|November 22, 2019
Discovery of Amino-cyclobutarene-derived Indoleamine-2,3-dioxygenase 1 (IDO1) Inhibitors for Cancer ImmunotherapyHongjun Zhang, Kun Liu, Qinglin Pu, et al.
Journal of Medicinal Chemistry|June 26, 2024
Discovery of MK-1084: An Orally Bioavailable and Low-Dose KRAS<sup>G12C</sup> InhibitorXiaoshen Ma, David L Sloman, Ruchia Duggal, et al.
Journal of Medicinal Chemistry|April 9, 2026
From KRAS<sup><i>G12D</i></sup> to Pan-KRAS Inhibitors─A Journey Enabled by Synthetic Innovation and Structure-Based Drug DesignXiaoshen Ma, David L Sloman, Timothy J Henderson, et al.
Journal of Medicinal Chemistry|March 3, 2022
Oxetane Promise Delivered: Discovery of Long-Acting IDO1 Inhibitors Suitable for Q3W Oral or Parenteral DosingDerun Li, David L Sloman, Abdelghani Achab, et al.
Pageof 3